The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...

AstraZeneca PLC AZN shares inched down 0.99% to £117.80 Friday, on what proved to be an all-around rough trading session for ...

The AstraZeneca PLC ADR AZN slumped 0.66% to $78.38 Friday, on what proved to be an all-around mixed trading session for the ...

AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain ...

In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...

Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...

However, Deutsche Bank downgraded AstraZeneca stock from Hold to Sell due to concerns over the company's TROP2 asset datopotamab. On the other hand, BMO Capital, Erste Group, TD Cowen, and BofA ...

and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements. AZN Price Action: AstraZeneca stock is down 0.16% at $78.41 at publication Wednesday.

However, Deutsche Bank (ETR:DBKGn) downgraded AstraZeneca stock from Hold to Sell due to concerns over the company's TROP2 asset datopotamab. On the other hand, BMO Capital, Erste Group, TD Cowen, and ...

Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...